Abstract LB-185: The effects of plasma folate and other B vitamins on breast cancer risk in BRCA1 and BRCA2 mutation carriers
Notice bibliographique
Résumé
Abstract Background: Women who inherit a deleterious BRCA mutation face a high lifetime risk of developing breast cancer, estimated at 80% compared with 11% in the general population. Current prevention options are limited to prophylactic surgery (removal of the breast and/or ovaries) and/or chemoprevention. Nonsurgical prevention options including dietary and lifestyle recommendations are highly desired by this population but have yet to be elucidated. Folate and other B-vitamins involved in folate metabolism are of particular interest given their essential roles in DNA synthesis and maintaining genomic stability, the reported dual effects on carcinogenesis (promoting or preventing), and the high levels of intake due to mandatory food fortification and supplement use. Given the heightened predisposition for cancer development among BRCA mutation carriers, clarifying the role of these nutrients on breast cancer development in this population is of extreme importance. Objectives: To prospectively investigate the relationship between plasma folate, B12 and B6 levels and the risk of breast cancer in women with a BRCA1 or BRCA2 mutation. Methods: We included 169 Canadian women who provided a blood sample at enrollment and had no history of cancer from an on-going international cohort of BRCA mutation carriers, the Risk Factor Analysis of Hereditary Breast and Ovarian Cancer Study. Baseline and biennial follow-up questionnaires collected relevant information regarding family, reproductive and medical histories, selected lifestyle factors, and disease incidence. Plasma folate and B12 levels were determined with microbiological microtitre assays, methylmalonic acid (MMA, a functional biomarker of vitamin B12) was quantified using reversed-phase LC-tandem mass spectrometry, and pyridoxal 5′-phosphate (PLP) measuring active B6 was determined with a non-radioactive apo-enzymatic assay. Cox proportional hazards models were used to estimate relative risks and 95% confidence intervals. Results: During a mean follow-up of 8 years, 21 women were diagnosed with invasive breast cancer. At baseline, the participants had a mean age of 52.7 ± 12.2 years and BMI of 25.0 ± 5.0 kg/m2. The mean plasma folate level was 17.8 ng/mL ± 11.9, ranging from 0.24 to 68.5 ng/mL. Unaffected women had an average plasma folate level of 21.7 ng/mL compared to 19.2 ng/mL in affected women (P = 0.46). Plasma B12 and B6 assays are currently underway. Results from statistical analyses are expected in March 2015. Impact: To our knowledge, this represents the first prospective study evaluating the effect of folate and other B vitamins on the risk of breast cancer among women with a BRCA1 or BRCA2 mutation. The results from this study will help develop safe and targeted recommendations for prevention in genetically predisposed women. Funding: Canadian Institutes of Health Research, Canadian Gene Cure Foundation. Citation Format: Shana J. Kim, Anna Zuchniak, Young-In Kim, Yvonne Lamers, Joanne Kotsopoulos, Steven Narod. The effects of plasma folate and other B vitamins on breast cancer risk in BRCA1 and BRCA2 mutation carriers. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr LB-185. doi:10.1158/1538-7445.AM2015-LB-185
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction machine sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Le volet Gemma est une étiquette directe du modèle pour chaque travail de la base, lue sur la notice réduite au titre. Le volet Codex est un classifieur appris des 10 348 étiquettes directes de Codex et calibré sur les taux pondérés de l'échantillon; les champs sans appui suffisant ne portent aucun appel Codex. Le mode candidate est l'union des deux volets; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont pas des étiquettes humaines.
Scores du classifieur distillé par catégorie (deux têtes)
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,000 | 0,001 |
| Méta-épidémiologie (sens strict) | 0,000 | 0,000 |
| Méta-épidémiologie (sens large) | 0,000 | 0,000 |
| Bibliométrie | 0,001 | 0,001 |
| Études des sciences et des technologies | 0,001 | 0,000 |
| Communication savante | 0,000 | 0,000 |
| Science ouverte | 0,000 | 0,000 |
| Intégrité de la recherche | 0,000 | 0,000 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,002 | 0,000 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule source (Gemma direct ou Codex distillé), pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».